Detalhe da pesquisa
1.
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
N Engl J Med
; 389(1): 22-32, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345876
2.
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
N Engl J Med
; 387(21): 1957-1968, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36346079
3.
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy.
Gastroenterology
; 166(1): 168-177.e8, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769952
4.
The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
Hepatology
; 79(2): 425-437, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611260
5.
Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.
Hepatology
; 79(3): 690-703, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37625144
6.
Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
Cancer
; 130(9): 1693-1701, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165808
7.
Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
J Hepatol
; 80(1): 31-40, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827470
8.
Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.
J Hepatol
; 80(4): 553-563, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101755
9.
Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B.
J Hepatol
; 80(1): 41-52, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37858684
10.
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
J Hepatol
; 80(1): 20-30, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37734683
11.
Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
J Hepatol
; 80(2): 243-250, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37898348
12.
Hepatitis B.
Lancet
; 401(10381): 1039-1052, 2023 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774930
13.
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion.
Clin Gastroenterol Hepatol
; 22(3): 581-590.e6, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871842
14.
Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events.
Clin Gastroenterol Hepatol
; 22(3): 591-601.e3, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040276
15.
A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 22(3): 602-610.e7, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993034
16.
Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure.
Gastroenterology
; 164(1): 42-60.e6, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243037
17.
Characteristics and clinical treatment outcomes of chronic hepatitis B children with coexistence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg.
BMC Med
; 22(1): 77, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378606
18.
A genetic variant of CXCR4 predicts pegylated interferon-alpha treatment response in HBeAg-positive chronic hepatitis B patients.
J Clin Microbiol
; 62(2): e0139623, 2024 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38259071
19.
Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles.
J Virol
; 97(10): e0072223, 2023 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37754761
20.
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
HIV Med
; 25(2): 291-298, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37816492